Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Current Liabilities (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Total Current Liabilities for 5 consecutive years, with $102.9 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 0.93% to $102.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $102.9 million through Dec 2025, up 0.93% year-over-year, with the annual reading at $102.9 million for FY2025, 0.93% up from the prior year.
  • Total Current Liabilities hit $102.9 million in Q4 2025 for Krystal Biotech, up from $91.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $102.9 million in Q4 2025 to a low of $9.1 million in Q1 2021.
  • Historically, Total Current Liabilities has averaged $51.6 million across 5 years, with a median of $35.4 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 560.95% in 2022 and later plummeted 41.96% in 2023.
  • Year by year, Total Current Liabilities stood at $25.7 million in 2021, then increased by 12.09% to $28.8 million in 2022, then grew by 14.72% to $33.1 million in 2023, then skyrocketed by 208.2% to $102.0 million in 2024, then increased by 0.93% to $102.9 million in 2025.
  • Business Quant data shows Total Current Liabilities for KRYS at $102.9 million in Q4 2025, $91.3 million in Q3 2025, and $86.9 million in Q2 2025.